Xalud Therapeutics is pioneering a non-viral plasmid DNA (pDNA)-delivered gene therapy platform aimed at treating chronic inflammation by restoring immune system balance. Their lead candidate, XT-150, utilizes a modified version of interleukin-10 (IL-10v), a potent anti-inflammatory cytokine that plays a crucial role in regulating inflammatory responses. By focusing on the root causes of inflammation rather than merely alleviating symptoms, Xalud's approach seeks to address a range of chronic inflammatory conditions, including osteoarthritis, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). The technology is designed for local administration, allowing for durable expression and the potential for redosing without the risks associated with viral delivery methods.

The innovative pDNA platform developed by Xalud offers significant advantages, including a non-immunogenic profile and the ability to deliver therapeutic agents safely to a variety of tissues. This technology expands the potential applications of gene therapy beyond rare genetic disorders to more prevalent chronic diseases. XT-150 has shown promise in clinical trials, demonstrating a longer duration of effect compared to traditional IL-10 therapies, which are often limited by rapid clearance from the body. By directly injecting XT-150 into areas of chronic inflammation, the therapy enhances the body’s natural IL-10 activity, providing a targeted and effective treatment option for patients suffering from debilitating inflammatory conditions.

United States

Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.

The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.

Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.

Xalud Therapeutics

Company Details